GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
02. März 2023 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
09. Januar 2023 07:30 ET
|
GH Research PLC
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
10. November 2022 07:05 ET
|
GH Research PLC
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
23. August 2022 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
18. Mai 2022 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
28. März 2022 07:04 ET
|
GH Research PLC
DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and...
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
06. Dezember 2021 07:10 ET
|
GH Research PLC
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
06. Dezember 2021 07:00 ET
|
GH Research PLC
Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change...
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
23. September 2021 17:25 ET
|
GH Research PLC
DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...